CELLARTIS
Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine Since 2001, Cellartis has worked globally with industry and academia, platform providers and end users to develop the next generation of advanced stem cell products and technologies. The company leverages a deep experience in stem cell handling, scale up and differentiation into mature and functional human cells. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today.
CELLARTIS
Industry:
Biotechnology
Founded:
2001-01-01
Address:
Göteborg, Vastra Gotaland, Sweden
Country:
Sweden
Website Url:
http://www.cellectis-stemcells.com
Total Employee:
51+
Status:
Active
Contact:
46 31 758 09 00
Email Addresses:
[email protected]
Total Funding:
8 M EUR
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Genedata AG
Genedata develops sophisticated computational solutions for drug discovery and related research processes in the life sciences.
Investors List
BioFund Management
BioFund Management investment in Venture Round - Cellartis
T-bolaget
T-bolaget investment in Venture Round - Cellartis
Catella Healthcare Investments
Catella Healthcare Investments investment in Venture Round - Cellartis
Innovations Kapital
Innovations Kapital investment in Venture Round - Cellartis
Official Site Inspections
http://www.cellectis-stemcells.com
Unable to get host informations!!!
More informations about "Cellartis"
About - Cellectis
Cellectis is committed to good corporate governance, which promotes the long-term interests of shareholders, strengthens the Board of Directors and management accountability and helps build public trust in the Company. Our …See details»
Corporate Governance - Cellectis
Kyung Nam-Wortman joined Cellectis in November 2020 as Executive Vice President, Chief Human Resources Officer. Ms. Nam-Wortman’s role is to ensure that the Company advances …See details»
Cellectis - Wikipedia
Cellectis was founded by André Choulika in 1999. [2] It built up a successful business based on the use of Meganuclease in genome engineering.Cellectis became a publicly traded company …See details»
Cellectis - LinkedIn
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to …See details»
Cellectis Company Profile - Office Locations, Competitors, Revenue ...
Oct 29, 2024 Cellectis has 5 employees across 3 locations and $41.51 m in annual revenue in FY 2024. See insights on Cellectis including office locations, competitors, revenue, financials, …See details»
AstraZeneca completes equity investment agreement with Cellectis
May 6, 2024 AstraZeneca today announced the successful completion of an equity investment with Cellectis, a clinical-stage biotechnology company. The equity investment and a research …See details»
Cellartis - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 46 31 758 09 00 Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative …See details»
Corporate Presentation - Cellectis
Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer.See details»
Cellartis AB - Company Profile - Tracxn
Feb 15, 2025 Cellartis AB operates as a subsidiary of Cellectis. Key Metrics. Total Funding. $9.45M in 1 round. Latest Funding Round. Series A, Dec 13, 2005, $9.45M. Investors. …See details»
Cellectis Reports Financial Results for the First Quarter
19 hours ago Net Income (loss) Attributable to Shareholders of Cellectis: Consolidated net loss attributable to shareholders of Cellectis was $18.1 million (or a $0.18 loss per share) for the …See details»
Cellectis 2025 Company Profile: Stock Performance & Earnings
Cellectis General Information Description. Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene …See details»
Company: Cellectis - CRISPR Medicine
Cellectis develops next generation allogeneic CAR-T cell therapies using its proprietary Transcription activator-like effector nuclease (TALEN) technology. The company has multiple …See details»
Cellectis (CLLS) Company Profile & Description - Stock Analysis
Feb 7, 2007 Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product …See details»
Our Mission - Cellectis
2005: Breakthrough: Cellectis enables the industrial production of nucleases. Cellectis research teams provide proof of the in vivo efficacy of meganucleases, the molecular "scissors" that …See details»
Cellectis - app.biopharmiq.com
About: Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical …See details»
Cellectis Reports Financial Results for the First Quarter 2025
19 hours ago About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company …See details»
Cellectis rockets on gene-editing alliance with AstraZeneca
Nov 1, 2023 Shares in Cellectis shot up this morning after the French biotech revealed a wide-ranging alliance with AstraZeneca, which includes $245 million in near-term financial …See details»
Investors - Cellectis
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update. Read more Key upcoming events 13 May 2025 ‐ 17 May 2025 28th …See details»
Cellectis Reports Financial Results for the First Quarter 2025
19 hours ago Cellectis will present novel non-viral gene editing and base editing research at the 2025 ASGCT annual meeting Cash position of $246 million as of March 31, 2025 1 provides …See details»
Products - Cellectis
Cellectis is pioneering robust first-in-class allogeneic CAR T-cell programs that address multiple unmet cancer needs. These programs were designed with simplicity, availability and cost …See details»